Abstract:Purpose: To compare prospectively the effects of radiofrequency (RF) ablation after transcatheter arterial chemoembolization (TACE) with those of RF ablation alone in the treatment of recurrent hepatocellular carcinoma (HCC). Materials and Methods: This study was approved by the institutional ethics committee, and all patients gave written informed consent. From January 2002 to December 2006, 139 patients with recurrent HCC measuring 5 cm in diameter or smaller were randomized to receive either sequential TACE and RF ablation (sequential treatment group, n = 69) or RF ablation alone (RF ablation group, n = 70). The survival curves were constructed with the Kaplan-Meier method and compared by using the log-rank test. Bonferroni correction was applied when multiple comparisons were performed. P < .0083 (.05 divided by 6) was considered indicative of a statistically significant difference. Results: The 1-, 3-, and 5-year overall survival rates were 94%, 69%, and 46%, respectively, for the sequential treatment group and 82%, 47%, and 36% for the RF ablation group (P = .037). The corresponding recurrence-free survival rates were 80%, 45%, and 40% for the sequential treatment group and 64%, 18%, and 18% for the ablation group (P = .005). At subgroup analyses, the overall survival for the sequential treatment group was better than that for the RF ablation group for patients with tumor recurrence 1 year or less after initial treatment (P = .004) and those with tumors measuring 3.1-5.0 cm (P = .002) but not for those with tumor recurrence more than 1 year after initial treatment (P = .421) and those with tumors 3.0 cm or smaller (P = .478). The recurrence-free survival in the sequential treatment group was better than that in the RF ablation group for patients with tumors measuring 3.1-5.0 cm (P < .001) but not for those with tumors 3.0 cm or smaller (P = .204). For recurrence-free survival, there was no significant difference between the two groups for patients with tumor recurrence 1 year or less or more than 1 year after initial treatment (P = .020 and P = .111, respectively). Logistic regression analysis showed that treatment allocation and the interval between initial treatment and tumor recurrence were significant prognostic factors for overall survival, whereas the interval between initial treatment and tumor recurrence, treatment allocation, and tumor size were significant prognostic factors for recurrence-free survival. Conclusion: The efficacy of sequential TACE-RF ablation is better than that of RF ablation alone for recurrent HCC. (C)RSNA, 2011

The role of neoadjuvant conventional transarterial chemoembolization with radiofrequency ablation in the treatment of recurrent hepatocellular carcinoma after initial hepatectomy with microvascular invasion

Surgical Resection Plus Radiofrequency Ablation for the Treatment of Multifocal Hepatocellular Carcinoma.

The Efficacy of Radiofrequency Ablation Combined with Transcatheter Arterial Chemoembolization for Primary Hepatocellular Carcinoma in a Cohort of 487 Patients

Combination therapy of radiofrequency ablation and transarterial chemoembolization in recurrent hepatocellular carcinoma after hepatectomy compared with single treatment.

Recurrent hepatocellular carcinoma treated with sequential transcatheter arterial chemoembolization and RF ablation versus RF ablation alone: a prospective randomized trial.

Radiofrequency Ablation with or Without Transcatheter Arterial Chemoembolization in the Treatment of Hepatocellular Carcinoma: a Prospective Randomized Trial.

Treatment Selection of Recurrent Hepatocellular Carcinoma with Microvascular Invasion at the Initial Hepatectomy

A Prospective Study of Radiofrequency Ablation Combined with Systematic Neoadjuvant Therapy in the Treatment of Recurrent Hepatocellular Carcinoma (RANT Study).

Radiofrequency ablation combined with transcatheter arterial chemoembolization for recurrent liver cancer

Combined transcatheter arterial chemoembolization and radiofrequency ablation versus hepatectomy for recurrent hepatocellular carcinoma after initial surgery: a propensity score matching study

Effectiveness of Radiofrequency Ablation Combined with Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma

Long-term Outcomes of Transcatheter Arterial Chemoembolization Combined With Radiofrequency Ablation as an Initial Treatment for Early-Stage Hepatocellular Carcinoma

Extrapolating Prognostic Factors of Primary Curative Resection to Postresection Recurrences Hepatocellular Carcinoma Treatable by Radiofrequency Ablation

Radiofrequency Ablation Following First-Line Transarterial Chemoembolization for Patients with Unresectable Hepatocellular Carcinoma Beyond the Milan Criteria

Combination Therapy with PD-1 Blockade and Radiofrequency Ablation for Recurrent Hepatocellular Carcinoma：a Retrospective Study

CT-guided Radiofrequency Ablation after with Transarterial Chemoembolization in Treating Unresectable Hepatocellular Carcinoma with Long Overall Survival Improvement.

IDDF2019-ABS-0094 Tumor Size and Location Affecting the Treatment Selection for Solitary Small Recurrent Hepatocellular Carcinoma (≤3.0 Cm) after Initial Hepatectomy

Adjuvant Sorafenib Following Radiofrequency Ablation for Early-Stage Recurrent Hepatocellular Carcinoma With Microvascular Invasion at the Initial Hepatectomy

Radio-frequency Ablation in Treatment of Intrahepatic Recurrence Following Liver Transplantation for Hepatocellular Carcinoma

[Percutaneous Radiofrequency Ablation Combined with Other Minimally Invasive Treatments for Recurrent Hepatocellular Carcinoma after Hepatectomy].

Transarterial Chemoembolization versus Radiofrequency Ablation for Recurrent Hepatocellular Carcinoma after Resection within Barcelona Clinic Liver Cancer Stage 0/A: A Retrospective Comparative Study.